Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Tardive Dyskinesia Therapeutics Market Size Changed, over the years?

In recent times, a notable escalation has been observed in the size of the market for tardive dyskinesia therapeutics. The market, which was worth $2.9 billion in 2024, is predicted to expand to $3.12 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. The surge during the historic period is attributed to various factors, namely an increase in tardive dyskinesia occurrences, the global increase in patients affected by schizophrenia and bipolar disorder, growing recognition and diagnosis, an increased use of both typical and atypical antipsychotic drugs, and an aging population.

How Much Will the Tardive Dyskinesia Therapeutics Market Be Worth in 2029?

Expectations are high for the tardive dyskinesia therapeutics market as robust growth is projected in the coming years. By 2029, the market is set to expand to $4.11 billion, with a compound annual growth rate (CAGR) of 7.2%. The anticipated growth within this period can be linked to several factors such as the escalating burden of mental health disorders, increased research and development endeavors, a surge in pharmaceutical company investments, a growing propensity for personalized medicine, and enhancements in healthcare infrastructure. Foreseen trends in this period include partnerships between pharmaceutical firms and research institutions for unique therapies, the creation of extended-release formulations, the introduction of generics, regulatory boosts like orphan drug designation, and technological progress in drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24718&type=smp

Which is the Largest Company in the Tardive Dyskinesia Therapeutics Market?

Major companies operating in the tardive dyskinesia therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lundbeck A/S, Amneal Pharmaceuticals Inc., Lupin Pharmaceuticals Inc., Neurocrine Biosciences Inc., Luye Pharma Ltd., Lannett Co. Inc., SteriMax Inc., Zydus Cadila Healthcare Ltd., Adamas Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, SOM Biotech Ltd., Addex Therapeutics

What Are the Main Market Drivers in the Tardive Dyskinesia Therapeutics Industry?

The tardive dyskinesia therapeutics market is forecasted to grow due to the increasing frequency of mental health issues. These issues, which can influence an individual’s thoughts, emotions, and daily functioning, are intensified by heightened feelings of loneliness and emotional stress due to a shift towards digital means of communication and accelerating lifestyles, leading to a lack of meaningful face-to-face interactions. Therapies for tardive dyskinesia, a condition characterized by involuntary movements resulting from extended usage of antipsychotics, aid patients by managing these symptoms, ensuring better adherence to treatment, and enhancing their overall quality of life. For example, it was reported by the National Alliance On Mental Illness based in the US that psychosis spectrum and mood disorders lead to roughly 600,000 hospitalizations annually among the 18-44 age group in the U.S.! As such, the escalating occurrence of mental health disorders is fuelling the growth of the tardive dyskinesia therapeutics market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24718&type=smp

How Is the Tardive Dyskinesia Therapeutics Market Segments Structured?

The tardive dyskinesia therapeutics market covered in this report is segmented –

1) By Drug: Deutetrabenazine, Valbenazine, Other Drugs

2) By Product Type: Solid Dosage Forms, Tablets, Capsules, Liquid Dosage Form, Injection

3) By Application: Antipsychotic-Induced Tardive Dyskinesia, Other Drug-Induced Tardive Dyskinesia, Idiopathic Tardive Dyskinesia

4) By End-User: Hospitals, Clinics, Specialty Treatment Centers, Homecare Settings

Sub Segments:

1) By Deutetrabenazine: Dosage Forms, Line Of Therapy, Distribution Channel

2) By Valbenazine: Dosage Forms, Patient Age Group, Distribution Channel

3) By Other Drugs: Drug Class Or Type, Dosage Forms, Treatment Duration

What Strategic Trends Are Transforming the Tardive Dyskinesia Therapeutics Market?

Prominent enterprises in the tardive dyskinesia therapeutics market are honing their focus on the creation of superior products like once-daily treatment solutions, aimed at keeping drug concentrations more stable in the body. These types of treatments are formulated to be administered once per day, making dosing regimens less complicated and increasing the likelihood of patient compliance. For instance, in May 2024, Israel-based biopharmaceutical enterprise Teva Pharmaceutical Industries Limited received approval from the U.S. Food and Drug Administration (FDA) for their AUSTEDO XR tablets. These are intended for the treatment of adults suffering from tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. The recent sanction of AUSTEDO XR allows patients the benefit of proven efficacy in the control of involuntary movements, enhanced by the convenience of a once-daily, single-pill dose. This novel formulation delivers clinically therapeutic doses validated by critical clinical trials. Moreover, it can now be availed in four distinct tablet strengths: 30 mg, 36 mg, 42 mg, and 48 mg.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/tardive-dyskinesia-therapeutics-global-market-report

Which Global Regions Offer the Highest Growth in the Tardive Dyskinesia Therapeutics Market?

North America was the largest region in the tardive dyskinesia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tardive dyskinesia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24718

This Report Delivers Insight On:

1. How big is the tardive dyskinesia therapeutics market, and how is it changing globally?

2. Who are the major companies in the tardive dyskinesia therapeutics market, and how are they performing?

3. What are the key opportunities and risks in the tardive dyskinesia therapeutics market right now?

4. Which products or customer segments are growing the most in the tardive dyskinesia therapeutics market?

5. What factors are helping or slowing down the growth of the tardive dyskinesia therapeutics market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model